Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4543544 | 0.82 | TYRO3 (0.34) | CYP1A2CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL4563134 | 0.70 | MAPT (0.35) | CYP1A2CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL4390910 | 0.67 | MAPT (0.61) | CYP1A2CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL4543941 | 0.67 | MAPT (0.38) | CYP1A2CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL2188149 | 0.66 | MAPT (0.37) | CYP1A2CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL5670554 | 0.65 | MAPT (0.59) | CYP1A2CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL2220058 | 0.64 | CACNA1G (0.30) | — | |
| SCHEMBL2215614 | 0.64 | MEN1 (0.31) | — | |
| SCHEMBL2176692 | 0.62 | MAPT (0.52) | CYP1A2CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL2172030 | 0.62 | MAPT (0.51) | CYP1A2CYP3A4MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | CYP1A2 3488/4885CYP3A4 3497/4885MAPT 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.